University of Miami, Sylvester Comprehensive Cancer Center

Site:	University of Miami, Sylvester Comprehensive Cancer Center	Go to their website
Address:	1475 Northwest 12th Ave
City:	Miami
State:	FL
Zip:	33136
Country:	USA

25 trials at this site

Phase	Trial	Trial Status	Site Status [asc]	Drug	NCT#
1/2	A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies	Recruiting	Active	DCC-3116 + Ripretinib	NCT05957367
3	Masitinib 2nd Line versus Sunitinib in Advanced GIST	Unknown	Active	Masitinib or Sunitinib	NCT01694277
3	A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment	Terminated	Active	Masitinib, (AB1010)	NCT00812240
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT05208047
3	A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)	Recruiting	Active	Ripretinib	NCT05734105
2	Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor	Active, not recruiting	Active	Temozolomide	NCT03556384
2	Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Active	Rogaratinib	NCT04595747
2	ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST	Recruiting	Active	ctDNA plus Sunitinib or Regorafenib	NCT05366816
1	A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]	Recruiting	Active	IDRX-42	NCT05489237
1/2	A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)	Active, not recruiting	Closed	THE-630	NCT05160168
3	Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST	Active, not recruiting	Closed	Crenolanib (CP-868,596)	NCT02847429
2	Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas	Active, not recruiting	Closed	Axitinib + Pembrolizumab	NCT02636725
2	Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma	Completed	Closed	Nivolumab + Ipilimumab	NCT02500797
2	Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study	Active, not recruiting	Closed	CB-839	NCT03872427
1	A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients	Completed	Closed	Imatinib + BYL719	NCT01735968
1	PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors	Completed	Closed	PLX9486 + PLX3397	NCT02401815
1	Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma	Suspended	Closed	Dendritic Cell Vaccine	NCT01803152
1	Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma	Ongoing, but not recruiting	Closed	ARQ 092	NCT01473095

University of Miami, Sylvester Comprehensive Cancer Center

25 trials at this site

Page 1 of 2 | Next | Last